Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
about
Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors.Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectivesPrimary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals
P2860
Q30253028-118E0FDD-34D5-4FB4-8E46-B5375D48CAFAQ37683243-6D0F4FE1-4E6C-4230-8F58-DD584CA75569Q38861953-73D2EDCB-E961-4CE8-BC23-F2EAC3148DD6Q39332785-D5D222E9-137B-447F-9531-6735ED985771Q39441629-9F8990E3-269E-49A3-9050-BF4DE2662842Q47257079-3BCA20D5-680D-4FF5-BDA4-B8747E008299Q48709352-A67C9CBD-32B8-400D-92AE-E0844AD5BB2EQ49337608-C1DDB630-4EE1-4D3F-B6CB-551E62081B78Q49894154-58F6D4B8-55F6-490E-9729-7ED7C5FE1FCDQ50157919-0AD6B08D-79D3-4AE5-BA54-DFE65107EE92Q55008645-BAA7EF26-3FB5-4A00-AC09-B2E9631F4842Q57174233-54F84C28-7688-4EC0-A024-F9F77F8C68C5Q58751209-431A8C39-952A-4BD2-84D3-FE0E3A2091B2
P2860
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Neoadjuvant chemotherapy and p ...... a comprehensive cancer center.
@ast
Neoadjuvant chemotherapy and p ...... a comprehensive cancer center.
@en
type
label
Neoadjuvant chemotherapy and p ...... a comprehensive cancer center.
@ast
Neoadjuvant chemotherapy and p ...... a comprehensive cancer center.
@en
prefLabel
Neoadjuvant chemotherapy and p ...... a comprehensive cancer center.
@ast
Neoadjuvant chemotherapy and p ...... a comprehensive cancer center.
@en
P2093
P2860
P1433
P1476
Neoadjuvant chemotherapy and p ...... a comprehensive cancer center.
@en
P2093
Alexia Iasonos
Amr El Haraki
Ane Gerda Zahl Eriksson
Carol Aghajanian
Dennis S Chi
Douglas A Levine
Farah A Alvi
Ginger J Gardner
Nadeem R Abu-Rustum
Oliver Zivanovic
P2860
P304
P356
10.1016/J.YGYNO.2016.01.008
P407
P577
2016-01-08T00:00:00Z